• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Brodalumab effective in treating active psoriatic arthritis

byJon LiuandXu Gao
June 11, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Brodalumab was found to produce a 20% improvement in various clinical domains for patients with active psoriatic arthritis by week 12 of treatment. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Psoriatic arthritis (PsA) affects approximately up to 30% of patients with a history of psoriasis. In addition to skin manifestations, other symptoms that can produce severe disability include inflammation of small joints, enthesitis, bone and axial skeleton involvement. Interleukin-17 (IL-17) is one of several cytokines involved with the pathogenesis of PsA. High levels of IL-17 receptors and IL-17 positive T-cells have been identified in the synovial fluid of these patients. Brodalumab is a novel antibody directed against one of the IL-17 receptors.

This phase 2 study compared brodalumab against placebo in patients with active PsA (both non-exposed and exposed to prior biologic therapy) to a primary endpoint of 20% improvement of American College of Rheumatology (ACR) criteria at week 12. However, beyond the primary endpoint, this study then became an open-label trial up to week 52. Patients previously exposed to another biologic in the past responded similarly (in terms of improvement in ACR criteria) as compared to those who were biologic-naĂŻve in this study.

While clinical benefit was observed in the groups randomized to brodalumab, this study was not adequately powered to determine the optimal dose and regimen required for treatment of PsA. Furthermore, the long-term safety of brodalumab remains to be determined in the phase three study.

Click to read the study, published today in NEJM

Relevant Reading: The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

In-Depth [randomized controlled trial]: This study enrolled a total of 168 patients randomized 1:1:1 into the following groups: brodalumab 140mg, brodalumab 280mg and placebo. All participants had active psoriatic arthritis as determined by several validated clinical scores (e.g., DAS28, CDI, HAQ-DI). Baseline characteristics among the three groups were well-matched for age, gender, body mass index, duration since diagnosis, prior use of any therapies (DMARDs, biologics, steroids) and clinical scores indicating disease activity. The placebo group did enroll more patients with higher enthesitis and dactylitis scores. Primary outcome of ACR 20 response rate at week 12 were as follows: 37% for brodalumab 140mg (p=0.03), 39% for brodalumab 280mg (p=0.02), and 18% for placebo. Beyond this time point, the study became an open-label trial whereby all participants received 280mg brodalumab each week. In this part of the trial, as expected, brodalumab showed the most benefit in the ACR20 of those previously on placebo. There was not a significant difference in serious adverse events among patients on brodalumab or placebo. However, common adverse events such as upper respiratory tract infections, diarrhea and nausea were noted to be more common in the brodalumab-treated groups.

More from this author: Idelalisib plus rituximab improves progression-free survival in relapsed CLL, SSRI use during pregnancy not linked to increased risk of autism,Combo antifungal therapy most effective treatment for cryptococcal meningitis 

Image: CC/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Brodalumabpsoriatic arthritis
Previous Post

Combination CPAP, weight loss for obstructive sleep apnea offer no added benefit

Next Post

Primary melanoma regression may not be associated with reduced metastasis

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
StudyGraphics

#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis

December 16, 2021
Next Post
Teledermatology may be reliable in triaging inpatient dermatology consultations

Primary melanoma regression may not be associated with reduced metastasis

Successful regional implementation of pediatric chest pain algorithm

UK fails to reduce deaths of young people

Preoperative MRI may not benefit breast cancer patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.